RESUMO
This Letter to the Editor is a response to St-Jules and Fouque and their interpretation of postprandial hyperkalemia, especially regarding plant-based diets. Based on the reviewed literature review, potassium kinetic studies cited by the authors include only 1 study with a food-based intervention that actually showed reduced postprandial hyperkalemia with plant-based diets. The remainder of the studies used potassium salts or supplements that behave differently compared with whole plant foods. As such, we recommend avoiding restriction of whole plant foods in patients with chronic kidney disease when solely based on the theoretical risk of postprandial hyperkalemia.
Assuntos
Hiperpotassemia , Insuficiência Renal Crônica , Humanos , Hiperpotassemia/prevenção & controle , Dieta Baseada em Plantas , Cinética , Dieta , PotássioRESUMO
Metabolic acidosis is a frequent complication of chronic kidney disease. Although it is known to appear at advanced stages, many studies suggest a state of "global protonic retention" starting at early stages of the disease, responsible of tissue damage, particularly musculoskeletal, alteration of protidic metabolism and endocrine disorders, promoting malnutrition and chronic inflammation, and finally increasing mortality. The majority of international recommandations suggest of supplementation by alkali, most of the time by sodium bicarbonate, to struggle against this complication. An interesting alternative to correct acidosis would consist on the modulation of the endogenous production of acid by playing with the alimentary incomes. In fact, it has been demonstrated that some different types of food produce or consume protons during their metabolism. Low protein diet and rich fresh fruits and vegetables diet would manage to correct at least as well as the supplementation by sodium bicarbonate the metabolic acidosis, and to struggle against its complications, noteworthy by slowing the decline of glomerular filtration rate by limiting the toxic adaptative fibrotic mechanisms, demonstrated by the decrease of urinary tubulo-interstitial suffering markers. Of the condition of being well led, those diets do not seem to expose patients to an over-risk of malnutrition or hyperkaliemia. They therefore appear to be an attractive alternative, efficiency and safe, to fight against chronic kidney disease metabolic acidosis and its complications.
Assuntos
Acidose/dietoterapia , Insuficiência Renal Crônica/dietoterapia , Acidose/tratamento farmacológico , Acidose/etiologia , Acidose/prevenção & controle , Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia , Distúrbio Mineral e Ósseo na Doença Renal Crônica/prevenção & controle , Terapia Combinada , Dieta com Restrição de Proteínas , Proteínas Alimentares/efeitos adversos , Proteínas Alimentares/farmacocinética , Frutas , Humanos , Hiperpotassemia/prevenção & controle , Hipoalbuminemia/etiologia , Hipoalbuminemia/prevenção & controle , Inflamação , Desnutrição/etiologia , Política Nutricional , Prótons , Insuficiência Renal Crônica/complicações , Sarcopenia/etiologia , Sarcopenia/prevenção & controle , Bicarbonato de Sódio/uso terapêutico , VerdurasRESUMO
Potassium supplementation can be administered intravenously or orally with either immediate release or sustained release formulations. Sustained release potassium chloride allows for delayed absorption and peak effects. In the inpatient setting, it is important to monitor and prevent both hypokalemia and hyperkalemia. Our tertiary-care academic hospital created a clinical pathway for sustained release potassium chloride supplementation in the inpatient population. Our clinical pathway for sustained release potassium chloride creates dosing restrictions designed to prevent hyperkalemia, while allowing exceptions for patients with high requirements.
Assuntos
Centros Médicos Acadêmicos , Doenças Cardiovasculares/complicações , Procedimentos Clínicos/normas , Hiperpotassemia/prevenção & controle , Pacientes Internados , Cloreto de Potássio/administração & dosagem , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/tratamento farmacológico , Preparações de Ação Retardada , Relação Dose-Resposta a Droga , Humanos , Hiperpotassemia/sangue , Hiperpotassemia/etiologia , Potássio/sangueRESUMO
PURPOSE: To audit the use of GIK in terms of safety, haemodynamic effects, and impact on catecholamine dosage. MATERIALS AND METHODS: A retrospective, descriptive, evaluative audit of GIK use within the adult ICU of a London teaching hospital was conducted. Rescue therapy of GIK (up to 1.0Unitsinsulin/kg/h) was administered to improve cardiac function. Outcomes were ICU survival, change in cardiac index (CI) and blood lactate levels, events of hypoglycaemia, hyperglycaemia, hypokalaemia and hyperkalaemia, and discontinuation time of catecholamine inotropes. RESULTS: Of 85 patients treated with GIK, 13 (15.3%) survived their ICU stay and 9 (10.5%) were discharged home. In patients surviving until 72h, a trend of improved CI and lactate levels was seen, often with reductions in catecholamine dosing. Inotropes were discontinued in 35 (54%) patients. Severe hypoglycaemia (<2mmol/l), hyperglycaemia (>20mmol/l), hypokalaemia (<2.5mmol/l) and hyperkalaemia (>7mmol/l) during GIK affected 1, 6, 8 and 1 patients, respectively. These abnormalities were quickly identified. No measurable harm was noted. CONCLUSIONS: High-dose GIK can be safely used in critically ill patients, though blood glucose and potassium levels must be monitored frequently. GIK was associated with improved CI and blood lactate levels. Impact on survival requires prospective evaluation.
Assuntos
Estado Terminal/terapia , Insuficiência Cardíaca/tratamento farmacológico , Idoso , Glicemia/análise , Auditoria Clínica , Feminino , Glucose/uso terapêutico , Hemodinâmica/efeitos dos fármacos , Humanos , Hiperglicemia/epidemiologia , Hiperglicemia/prevenção & controle , Hiperpotassemia/epidemiologia , Hiperpotassemia/prevenção & controle , Hipocalcemia/epidemiologia , Hipocalcemia/prevenção & controle , Hipopotassemia/epidemiologia , Hipopotassemia/prevenção & controle , Incidência , Insulina/uso terapêutico , Londres/epidemiologia , Masculino , Pessoa de Meia-Idade , Potássio/sangue , Potássio/uso terapêutico , Estudos RetrospectivosAssuntos
Suplementos Nutricionais , Hipertensão/dietoterapia , Potássio na Dieta/uso terapêutico , Guias de Prática Clínica como Assunto , Anti-Hipertensivos/uso terapêutico , Canadá , Terapia Combinada , Relação Dose-Resposta a Droga , Frutas , Comportamentos Relacionados com a Saúde , Humanos , Hiperpotassemia/prevenção & controle , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Educação de Pacientes como Assunto , Sódio na Dieta/efeitos adversos , VerdurasRESUMO
Introducción: Con el fin de prevenir una posible hiperpotasemia, los enfermos renales crónicos, especialmente en fases avanzadas, deben seguir una dieta baja en potasio. Para ello, las guías alimentarias para la enfermedad renal crónica recomiendan limitar el consumo de muchas verduras, así como aplicar laboriosas técnicas culinarias para reducir al máximo la cantidad de potasio. Objetivos: El objetivo de este trabajo es analizar el contenido de potasio de varios productos vegetales (frescos, congelados y en conserva), así como comprobar y comparar la efectividad en la reducción de potasio de distintos procesos culinarios, algunos de ellos recomendados en las guías alimentarias, como son el remojo o la doble cocción. Métodos: Se analizó el contenido de potasio de las muestras por triplicado mediante espectrometría de emisión atómica de llama. Resultados: Los resultados mostraron reducciones significativas en el contenido de potasio en todos los procesos culinarios estudiados. El grado de disminución varió según el tipo de verdura y el procesado al que fue sometida. En los productos congelados se alcanzaron mayores reducciones que en los frescos, y en algunos casos se lograron pérdidas de potasio superiores al 90%. Además, se observó como en muchos casos la simple aplicación de una cocción normal dio lugar a reducciones de potasio hasta niveles aceptables para la inclusión en la dieta del enfermo renal. Conclusión: Los resultados mostrados en este estudio son muy positivos, ya que aportan herramientas a los profesionales que tratan con este tipo de pacientes, lo que les permite adaptarse más fácilmente a las necesidades y preferencias de sus pacientes, así como incrementar la variedad en su dieta (AU)
Introduction: In order to prevent a possible hyperkalemia, chronic renal patients, especially in advanced stages, must follow a low potassium diet. So dietary guidelines for chronic kidney disease recommend limiting the consumption of many vegetables, as well as to apply laborious culinary techniques to maximize the reduction of potassium. Objective: The aim of this work is to analyze potassium content from several vegetable, fresh products, frozen and preserved, as well as check and compare the effectiveness in potassium reduction of different culinary processes, some of them recommended in dietary guidelines such as soaking or double cooking. Methods: Sample potassium content was analyzed by triplicate using flamephotometry. Results: The results showed significant reductions in potassium content in all culinary processes studied. The degree of loss varied depending on the type of vegetable and processing applied. Frozen products achieved greater reductions than the fresh ones, obtaining in some cases losses greater than 90%. In addition, it was observed how in many cases the single application of a normal cooking reached potassium reductions to acceptable levels for its inclusion in renal patient diet. Conclusion: The results shown in this study are very positive because they provide tools for professionals who deal with this kind of patients. They allow them to adapt more easily to the needs and preferences of their patients and increase dietary variety (AU)
Assuntos
Humanos , Potássio na Dieta/análise , Insuficiência Renal Crônica/terapia , Diálise Renal/métodos , Verduras/química , Hiperpotassemia/prevenção & controle , Manipulação de Alimentos , Beta vulgaris , Phaseolus , Espectrofotometria AtômicaRESUMO
Controlling the extracellular volume in hemodialysis patients is a difficult task. The aim of this study was to evaluate the capacity of different methods of stimulated sweating to reduce mean interdialytic weight gain (IWG), to improve blood pressure regulation, and potassium/urea balance. Two center, crossover pilot study. In Lausanne, hemodialysis patients took four hot-water baths a week, 30 minutes each, on nondialysis days during 1 month. In Sfax, patients visited the local Hammam Center four times a week. Hemodynamic parameters were recorded, and weekly laboratory analysis was performed. Results were compared with a preceding 1-month control period. In Lausanne, five patients (all men, median age 55 years) participated. Bathing temperature was (mean ± standard deviation) 41.2 ± 3°C and sweating-induced weight loss 600 ± 500 g. Mean IWG (control vs. intervention period) decreased from 2.3 ± 0.9 to 1.8 ± 1 kg (P = 0.004), Systolic blood pressure from 139 ± 21 to 136 ± 22 mmHg (P = 0.4), and diastolic blood pressure form 79 ± 12 to 75 ± 13 mmHg (P = 0.08); antihypertensive therapy could be reduced from 2.8 ± 0.4 to 1.9 ± 0.5 antihypertensive drugs per patient (P = 0.01). In Sfax (n = 9, median age 46 years), weight loss per Hammam session was 420 ± 100 g. No differences were found in IWG or BP, but predialysis serum potassium level decreased from 5.9 ± 0.8 to 5.5 ± 0.9 mmol/L (P = 0.04) and urea from 26.9 ± 6 to 23.1 ± 6 mmol/L (P = 0.02). Hot-water baths appear to be a safe way to reduce IWG in selected hemodialysis patients. Hammam visits reduce serum potassium and urea levels, but not IWG. More data in larger patient groups are necessary before definite conclusion can be drawn.
Assuntos
Hiperpotassemia/terapia , Hipertermia Induzida/métodos , Potássio/metabolismo , Diálise Renal/métodos , Sudorese/fisiologia , Ureia/metabolismo , Aumento de Peso , Adulto , Idoso , Feminino , Hemofiltração , Humanos , Hiperpotassemia/prevenção & controle , Hipertensão/prevenção & controle , Hipertensão/terapia , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Equilíbrio HidroeletrolíticoRESUMO
Computer-triggered reminders alerting physicians on every potentially harmful drug-drug-interaction (DDI) induce alert fatigue due to frequent messages of limited clinical relevance. On demand DDI-checks, however, are not commonly used by physicians. Optimal strategies for sustained quality assurance have to consider patients' risk factors and focus on the most significant DDIs only. An approach is proposed based on the analysis of concurrent prescription of potassium-sparing diuretics and potassium supplements (CPPP), which are the most frequent DDIs classified as contraindicated. Although the frequency of monitoring potassium serum levels declined during prolonged periods of CPPP, the likelihood of observing a hyperkalaemia increased. The median treatment period of CPPP was 3.3 days, whereas hyperkalaemia occurred after a median observation time of 4.5 days of CPPP. Thus, computer-triggered reminders for ordering potassium serum levels may be indicated if monitoring has been discontinued after 48h of CPPP.
Assuntos
Sistemas de Apoio a Decisões Clínicas/estatística & dados numéricos , Interações Medicamentosas , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Hiperpotassemia/sangue , Hiperpotassemia/induzido quimicamente , Potássio/sangue , Quimioterapia Assistida por Computador , Humanos , Hiperpotassemia/prevenção & controle , Sistemas de Alerta , Suíça/epidemiologiaRESUMO
BACKGROUND: Aldosterone antagonists have proven efficacy for management of resistant hypertension and proteinuria reduction; however, they are not widely used due to risk of hyperkalemia. This study assesses the risk factors for hyperkalemia in patients with chronic kidney disease (CKD) and resistant hypertension whose blood pressure (BP) is reduced to a guideline goal. METHODS: This is a two-center study conducted in university-based hypertension clinics directed by clinical hypertension specialists. Forty-six patients with resistant hypertension and stages 2 or 3 CKD (mean estimated glomerular filtration rate (eGFR) 56.5 + or - 16.2 ml/min/1.73 m(2)) were evaluated for safety and efficacy of aldosterone blockade added to preexisting BP-lowering regimens. All patients were on three mechanistically complementary antihypertensive agents including a diuretic and a renin-angiotensin system blocker. Patients were evaluated after a median of 45 treatment days. The primary endpoint was change in systolic BP. Secondary endpoints included change in serum potassium, creatinine, eGFR, diastolic BP and tolerability. RESULTS: The mean age of the patients studied was 64.9 + or - 10.7 years, all were obese and 86% had type 2 diabetes, with 82% being African-American. Addition of aldosterone antagonism yielded a further mean reduction in systolic BP of 14.7 + or - 5.1 mm Hg (p = 0.001). Females with BMI >30 and those with a baseline systolic BP >160 mm Hg were more likely to have a greater BP reduction to aldosterone antagonism. In total, 39% of the patients had a >30% decrease in eGFR when the BP goal was achieved. The mean increase in serum potassium was 0.4 mEq/l above baseline (p = 0.001), with 17.3% manifesting hyperkalemia, i.e. serum potassium >5.5 mEq/l. Predictors of hyperkalemia included a baseline eGFR of < or = 45 ml/min/1.73 m(2) in whom serum potassium was >4.5 mEq/l on appropriately dosed diuretics. Contributing risks in this subgroup included a systolic BP reduction of >15 mm Hg associated with an eGFR fall of >30%. CONCLUSION: Aldosterone antagonism is effective and safe for achieving a BP goal among people with diabetic nephropathy when added to a triple antihypertensive regimen that includes a blocker of the renin-angiotensin system and an appropriately selected and dosed diuretic. Caution is advised when using aldosterone blockade for BP control in people with advanced stage 3 nephropathy with a serum potassium of >4.5 mEq/l for safety reasons.
Assuntos
Hiperpotassemia/prevenção & controle , Hipertensão Renal/tratamento farmacológico , Antagonistas de Receptores de Mineralocorticoides/administração & dosagem , Espironolactona/administração & dosagem , Idoso , Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Quimioterapia Combinada , Eplerenona , Feminino , Humanos , Hiperpotassemia/induzido quimicamente , Hiperpotassemia/epidemiologia , Hipertensão Renal/epidemiologia , Masculino , Pessoa de Meia-Idade , Antagonistas de Receptores de Mineralocorticoides/efeitos adversos , Potássio/sangue , Valor Preditivo dos Testes , Proteinúria/tratamento farmacológico , Proteinúria/epidemiologia , Fatores de Risco , Espironolactona/efeitos adversos , Espironolactona/análogos & derivadosRESUMO
OBJECTIVE: To determine whether early and higher intravenous amino acid (EHAA) supplementation decreases hyperkalemia in extremely low birth weight (ELBW) infants (<1000 g). STUDY DESIGN: Infants were enrolled at birth in a randomized, double-masked, prospective fashion and treated for 7 days. The standard group (SAA) infants received intravenous amino acid (AA) starting at 0.5 g x kg(-1) x d(-1) and increased by 0.5 g x kg(-1) every day to a maximum of 3 g x kg(-1) x d(-1). EHAA group infants received 2 g x kg(-1) x d(-1) of AA soon after birth and advanced by 1 g x kg(-1) every day to 4 g x kg(-1) x d(-1). Data analysis was by SPSS 11.5, with statistical significance at alpha = 0.05 and 90% power to determine a difference in mean K(+) level of 2. RESULTS: Sixty-two patients, mean gestational age of 26.0 +/- 2.0 weeks and birth weight of 775 +/- 136 g, were enrolled. Hyperkalemia (K(+) > or =6.5 mEq/L) occurred in 13% of the studied population; no difference in incidence of hyperkalemia was found between the SAA and EHAA groups (16% vs 10%, respectively, P = .70). Serum blood urea nitrogen was higher in the EHAA group. AA infusion was stopped early in 6 patients for high blood urea nitrogen or elevated ammonia level. CONCLUSIONS: During the study period, hyperkalemia decreased significantly and was not affected by EHAA supplementation in the first week of life.
Assuntos
Aminoácidos/administração & dosagem , Suplementos Nutricionais , Hiperpotassemia/prevenção & controle , Recém-Nascido de Peso Extremamente Baixo ao Nascer/metabolismo , Doenças do Prematuro/prevenção & controle , Nutrição Parenteral Total , Nitrogênio da Ureia Sanguínea , Humanos , Hiperpotassemia/metabolismo , Recém-Nascido , Recém-Nascido Prematuro , Doenças do Prematuro/metabolismo , Estudos ProspectivosRESUMO
IMPLICATIONS: Long-stored packed red blood cells (PRBCs) have a large potassium load. In patients with end-stage renal failure, the transfusion of such PRBCs may cause a critical increase in plasma potassium levels. Washing PRBCs with an autotransfusion device allows for a marked decrease in potassium load, thus preventing hyperkalemia.
Assuntos
Transfusão de Sangue Autóloga/métodos , Transfusão de Eritrócitos/métodos , Hiperpotassemia/prevenção & controle , Complicações Intraoperatórias/prevenção & controle , Idoso , Transfusão de Sangue Autóloga/instrumentação , Hematócrito , Hemoglobinas/metabolismo , Humanos , Falência Renal Crônica/complicações , Falência Renal Crônica/metabolismo , Falência Renal Crônica/cirurgia , Masculino , Nefrectomia , Potássio/sangueRESUMO
Prescribed medications, over-the-counter drugs, and nutritional supplements are used by many patients. Although most of these products are well tolerated, drug-induced hyperkalemia may develop in patients with underlying renal impairment or other abnormalities in potassium handling. Drug-induced hyperkalemia most often occurs from impaired renal potassium excretion. However, disturbed cellular uptake of a potassium load as well as excessive ingestion or infusion of potassium-containing substances may also occur. Physicians must be aware of medications that can precipitate hyperkalemia, how these drugs induce alterations in potassium homeostasis, and the patient characteristics that increase the risk of hyperkalemia.
Assuntos
Suplementos Nutricionais/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Hiperpotassemia/induzido quimicamente , Feminino , Humanos , Hiperpotassemia/metabolismo , Hiperpotassemia/prevenção & controle , Rim/metabolismo , Masculino , Medicamentos sem Prescrição/efeitos adversos , Potássio/administração & dosagem , Potássio/efeitos adversos , Potássio/metabolismo , Prevenção Primária/métodos , Prognóstico , Medição de RiscoRESUMO
High-dose trimethoprim-sulfamethoxazole (TMP-SMX) causes hyperkalemia, thought to result from TMP-induced blockade of amiloride-sensitive Na(+)-channels in the distal nephron. The present study was performed in anesthetized dogs to determine if increasing distal sodium delivery affects this antikaliuretic effect. In Group 1, intrarenal infusion of vehicle did not alter renal function. In Group 2, i.v. infusion of amiloride led to diuresis, natriuresis and antikaliuresis associated with a reduction of the transtubular potassium gradient (TTKG) in both kidneys. Intrarenal infusion of TMP (0.2 mg/kg/min) into the left kidney did not further alter these parameters. In groups 3 and 4, intrarenal infusion of TMP caused an ipsilateral diuresis, natriuresis, antikaliuresis and a reduction in (TTKG) without affecting the contralateral kidney. The TMP infusion was followed by furosemide (20 mg i.v.) in group 3 and acute saline loading in group 4. Despite continuous TMP infusion, both furosemide and saline loading reversed the antikaliuretic effect of TMP in the ipsilateral kidney and was associated with a similar kaliuresis, diuresis, natriuresis and decrease in urine osmolality in both kidneys. The TTKG following furosemide or saline loading increased in the ipsilateral kidney and decreased in the contralateral kidney. In all groups the systemic and renal hemodynamics remained unchanged. These results suggest that acute administration of TMP inhibits the amiloride-sensitive Na(+)-channel and K+ secretion in the distal nephron. Maneuvers that increase distal Na+ delivery can abrogate TMP's antikaliuretic effect due, in part, to an increase of the low TTKG observed with TMP.
Assuntos
Anti-Infecciosos Urinários/toxicidade , Potássio/urina , Trimetoprima/toxicidade , Animais , Pressão Sanguínea/efeitos dos fármacos , Cães , Feminino , Furosemida/farmacologia , Concentração de Íons de Hidrogênio , Hiperpotassemia/induzido quimicamente , Hiperpotassemia/prevenção & controle , Túbulos Renais Coletores/metabolismo , Circulação Renal/efeitos dos fármacos , Sódio/urina , Bloqueadores dos Canais de SódioRESUMO
OBJECTIVE: To determine the effect of standard-dose trimethoprim/sulfamethoxazole (TMP/SMX) (TMP 160 mg and SMX 800 mg q12h) on the serum potassium concentration. DESIGN: Retrospective and concurrent study. SETTING: A Veterans Affairs Medical Center. PATIENTS: Fifty-three men hospitalized at the Fargo Veterans Affairs Medical Center. Thirty-three patients who received standard-dose TMP/SMX for 3 or more days comprised the study group. Twenty patients who received oral cephradine or amoxicillin for 3 or more days comprised the control group. Patients who received potassium supplements, potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, nonsteroidal antiinflammatory drugs, beta-blockers, heparin, known nephrotoxic agents, patients with a serum creatinine concentration of more than 177 mumol/L, and patients with baseline hyperkalemia (serum potassium concentration > 5.1 mmol/L) were excluded. RESULTS: The serum potassium concentration in the study group was 4.22 +/- 0.40 mmol/L and increased by 0.31 +/- 0.38 mmol/L at the end of therapy (p < 0.001). Twenty-six patients in the study group (78.8%) had an increase in the serum potassium concentration during TMP/SMX therapy. Fourteen of these patients had follow-up serum potassium concentrations obtained after completion of therapy. The serum potassium concentration returned to baseline in 10 of these patients. The serum creatinine concentration also increased during therapy. However, the correlation between the increase in the serum potassium concentration and the increase in the serum creatinine concentration was weak (Pearson r = 0.29). The serum potassium in the control group was 4.34 mmol/L and remained essentially unchanged during therapy. CONCLUSIONS: Therapy with standard-dose TMP/SMX is associated with a slight increase in the serum potassium concentration. Routine monitoring of the serum potassium concentration in patients who are treated with standard-dose TMP/SMX therapy is unnecessary. However, TMP/SMX should be considered as a possible cause of unexplained hyperkalemia in elderly patients receiving TMP/SMX therapy.
Assuntos
Anti-Infecciosos Urinários/farmacologia , Hiperpotassemia/prevenção & controle , Potássio/sangue , Combinação Trimetoprima e Sulfametoxazol/farmacologia , Idoso , Anti-Infecciosos Urinários/efeitos adversos , Infecções por HIV/tratamento farmacológico , Humanos , Hiperpotassemia/sangue , Hiperpotassemia/complicações , Masculino , Estudos Retrospectivos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversosRESUMO
Dietary modification is an inefficient and calorically unwise means of preventing hypokalemia; potassium supplements present compliance problems and are of little or no use in the patient with a concomitant magnesium deficiency. Prescribing potassium-sparing diuretics is the best prevention-oriented choice, but diabetics and older patients must be monitored for signs of hyperkalemia, and it is generally better not to use these agents in patients who are also taking ACE inhibitors.
Assuntos
Diuréticos/efeitos adversos , Hipopotassemia/prevenção & controle , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Complicações do Diabetes , Diuréticos/uso terapêutico , Interações Medicamentosas , Humanos , Hidroclorotiazida/uso terapêutico , Hiperpotassemia/prevenção & controle , Hipopotassemia/tratamento farmacológico , Potássio/uso terapêuticoRESUMO
After reviewing the available data on drug-induced hyperkalemia, we conclude that the situation has not improved since Lawson quantitatively documented the substantial risks of potassium chloride over a decade ago (90). As discussed, the risk of developing hyperkalemia in hospital remains at least at the range of 1 to 2% and can reach 10%, depending on the definition used (Table 2). Potassium chloride supplements and potassium-sparing diuretics remain the major culprits but they have been joined by a host of new actors, e.g., salt substitutes, beta-blockers, converting enzyme inhibitors, nonsteroidal antiinflammatory agents, and heparin, among others. Readily identifiable risk factors (other than drugs) for developing hyperkalemia are well-known but seem to be consistently ignored, even in teaching hospitals. The presence of diabetes mellitus, renal insufficiency, hypoaldosteronism, and age greater than 60 years results in a substantial increase in the risk of hyperkalemia from the use of any of the drugs we have reviewed. If prevention of hyperkalemia is the goal, as it should be, the current widespread and indiscriminate use of potassium supplements and potassium-sparing diuretics will need to end. We remain intrigued by Burchell's prescient pronouncement of over a decade ago that "more lives have been lost than saved by potassium therapy" (28).
Assuntos
Hiperpotassemia/induzido quimicamente , Potássio/metabolismo , Agonistas Adrenérgicos/efeitos adversos , Antagonistas Adrenérgicos beta/efeitos adversos , Idoso , Inibidores da Enzima Conversora de Angiotensina , Anti-Inflamatórios/efeitos adversos , Arginina/efeitos adversos , Compartimentos de Líquidos Corporais/metabolismo , Ciclosporinas/efeitos adversos , Glicosídeos Digitálicos/efeitos adversos , Diuréticos/uso terapêutico , Glucose/efeitos adversos , Heparina/efeitos adversos , Heroína/efeitos adversos , Hormônios/metabolismo , Humanos , Hiperpotassemia/etiologia , Hiperpotassemia/prevenção & controle , Soluções Hipertônicas , Rim/metabolismo , Transplante de Rim , Lítio/efeitos adversos , Carbonato de Lítio , Pessoa de Meia-Idade , Cloreto de Potássio/efeitos adversos , Cloreto de Potássio/uso terapêutico , Prostaglandinas/biossíntese , Risco , Reação TransfusionalRESUMO
Serum potassium (K+) levels were measured after thiopental, succinylcholine, pancuronium, and pretreatment with pancuronium prior to succinylcholine, in 100 patients divided into 4 groups of 25 patients each. Significant increases in serum K+ were found after succinylcholine (1 mg/kg). Administration of pancuronium in small doses (20 mug/kg) prior to succinylcholine (1 mg/kg) was effective not only in complete prevention of serum K+ elevation but also produced consistent decrease in serum K+ concentration below control values. Both thiopental and pancuronium produced moderate fall in serum K+ levels. Our observations indicate that pretreatment with pancuronium may play a beneficial role in patients at risk from succinylcholine hyperkalemia.